Evidence map›Paper›PMID 18973230›Full record

ArticleInternational journal of cancer2009

Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations.

Margaret A Gates, Shelley S Tworoger, Kathryn L Terry, Immaculata De Vivo, David J Hunter, Susan E Hankinson, Daniel W Cramer

Open access · bronzeAbstract read
In one paragraph

Article in International journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. No association between ovarian cancer susceptibility variants and breast cancer risk among Chinese women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2013
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Margaret A GatesChanning Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. nhmag@channing.harvard.edu
Shelley S Tworoger
Kathryn L Terry
Immaculata De Vivo
David J Hunter
Susan E Hankinson
Daniel W Cramer
Brigham and Women's Hospital · USHarvard University · US

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
Novel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3M
OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISMR01CA054419 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 1992 to 2007
$5.9M
Nutritional Epidemiology of Cancer Education and Career Development ProgramR25CA098566 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI STAMPFER, MEIR · 2003 to 2013
$4.5M
NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA87969NCI NIH HHS P50 CA105009NCI NIH HHS R01 CA054419NCI NIH HHS R25 CA098566
6 · The paper itself

Abstract

Recent genome-wide scans identified several novel breast cancer risk alleles, including variants of the FGFR2, MAP3K1 and LSP1 genes, and a study of associations between these alleles and characteristics of breast cancer patients reported a borderline significant correlation between the number of FGFR2 minor alleles and family history of breast/ovarian cancer. Given these results and similarities in the etiology of breast and ovarian cancer, we examined the association between 7 novel breast cancer susceptibility alleles and epithelial ovarian cancer risk in 2 large study populations. Our analysis included 1,173 cases and 1,201 controls from a New England-based Case-Control study and 210 cases and 603 controls from the prospective Nurses' Health Study. We used logistic regression to estimate the odds ratio (OR) for individuals heterozygous or homozygous for the minor allele at each locus, compared to individuals with the wild-type genotype. We examined the associations separately in each population and, after testing for heterogeneity in the results, pooled the estimates using a random effects model. There was no clear association between these polymorphisms and ovarian cancer risk in either population. The pooled per allele OR for FGFR2 was 1.06 (95% confidence interval (CI)=0.95-1.18) for rs1219648 and 1.04 (95% CI=0.93-1.15) for rs2981582. We had more than 80% power to detect a log-additive OR of 1.16-1.18 per allele at the alpha=0.05 level in the pooled analysis. Our results do not provide strong support for an association between these breast cancer susceptibility alleles and epithelial ovarian cancer risk.

Indexed as

AllelesGenetic Predisposition to DiseaseAdultBreast NeoplasmsCase-Control StudiesFemaleGenotypeHumansMAP Kinase Kinase Kinase 1Microfilament ProteinsMiddle AgedOvarian NeoplasmsPolymerase Chain ReactionPolymorphism, GeneticReceptor, Fibroblast Growth Factor, Type 2FGFR2 protein, humanLSP1 protein, humanMAP3K1 protein, humanMAP Kinase Kinase Kinase 1Microfilament ProteinsReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID18973230
PMCPMC2679694
OpenAlexW2084370890

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.